Evidence map›Paper›PMID 35510939›Full record

ArticleThe Journal of infectious diseases2022

Elevated Plasma Matrix Metalloproteinase 8 Associates With Sputum Culture Positivity in Pulmonary Tuberculosis.

N F Walker, F Karim, M Y S Moosa, S Moodley, M Mazibuko, K Khan, T R Sterling, Y F van der Heijden, A D Grant, P T Elkington and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 3 countries.

N F WalkerDepartment of Clinical Sciences, Liverpool School of Tropical Medicine and Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom.ORCID 0000-0002-3345-7694
F KarimAfrica Health Research Institute, KwaZulu-Natal, South Africa.
M Y S MoosaDepartment of Infectious Diseases, University of KwaZulu-Natal, Durban, South Africa.
S MoodleyAfrica Health Research Institute, KwaZulu-Natal, South Africa.
M MazibukoAfrica Health Research Institute, KwaZulu-Natal, South Africa.
K KhanAfrica Health Research Institute, KwaZulu-Natal, South Africa.
T R SterlingDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
Y F van der HeijdenDivision of Infectious Diseases, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
A D GrantTB Centre and Department of Clinical Research, London School of Hygiene and Tropical Medicine, London, United Kingdom.
P T ElkingtonNIHR Biomedical Research Centre, Clinical and Experimental Sciences, University of Southampton, Southampton, United Kingdom.
A PymAfrica Health Research Institute, KwaZulu-Natal, South Africa.
A LeslieAfrica Health Research Institute, KwaZulu-Natal, South Africa.
Africa Health Research Institute · ZAAurum Institute · ZALiverpool School of Tropical Medicine · GBLondon School of Hygiene & Tropical Medicine · GBNIHR Southampton Biomedical Research Centre · GBUniversity of KwaZulu-Natal · ZAVanderbilt University Medical Center · US

Funding

Fluoroquinolone resistance in patients with multidrug-resistant tuberculosisK08AI106420 · NIAID · VANDERBILT UNIVERSITY MEDICAL CENTER · PI VAN DER HEIJDEN, YURI F. · 2014 to 2018
$848k
Medical Research Council MR/P023754/1NIAID NIH HHS K08 AI106420Wellcome Trust 210662
6 · The paper itself

Abstract

Current methods for tuberculosis treatment monitoring are suboptimal. We evaluated plasma matrix metalloproteinase (MMP) and procollagen III N-terminal propeptide concentrations before and during tuberculosis treatment as biomarkers. Plasma MMP-1, MMP-8, and MMP-10 concentrations significantly decreased during treatment. Plasma MMP-8 was increased in sputum Mycobacterium tuberculosis culture-positive relative to culture-negative participants, before (median, 4993 pg/mL [interquartile range, 2542-9188] vs 698 [218-4060] pg/mL, respectively; P = .004) and after (3650 [1214-3888] vs 720 [551-1321] pg/mL; P = .008) 6 months of tuberculosis treatment. Consequently, plasma MMP-8 is a potential biomarker to enhance tuberculosis treatment monitoring and screen for possible culture positivity.

Indexed as

Matrix Metalloproteinase 8Tuberculosis, PulmonaryBiomarkersHumansMycobacterium tuberculosisSputumBiomarkersMatrix Metalloproteinase 8diagnosisHIVimmunopathologymatrix metalloproteinaseprocollagen III N-terminal propeptideTuberculosis

Identifiers

PMID35510939
PMCPMC9470104
OpenAlexW4226143000

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.